Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab (INCA034176) and Corticosteroids as Initial Treatment for Chroni… Recruiting

2023-510292-65-00 chronic graft-versus-host disease 5 2025-02-25
A Clinical Trial for Patients with Advanced Cancers Recruiting

2024-515020-36-00 Advanced Solid tumour 9 2025-02-24
Phase 2 Trial to determine the safety and efficacy of simultaneous treatment with ruxolitinib and extracorporeal photopheresis for patients … Recruiting

2023-507754-33-00 steroid-refractory chronic Graft-versus-Host-Disease 4 2025-02-19
Quantitative Fluorescence molecular imaging in Crohn’s disease and psoriasis Recruiting

2023-506192-10-00 Crohn's disease 1 2025-02-14
Immediate corticosteroid therapy and rituximab to prevent generalization in ocular myasthenia gravis: a PROBE-type multicenter, open-label, … Recruiting

2023-506656-24-00 Myasthenia gravis 5 2025-02-12
A Phase 2 Study to Evaluate DNTH103 in Adults with Multifocal Motor Neuropathy (MOMENTUM) Recruiting

2024-513128-40-00 Multifocal Motor Neuropathy 4 2025-02-06
A placebo-controlled, single-blind, phase I study in healthy volunteers and patients with Rheumatoid Arthritis with ABO21009 Recruiting

2024-517547-31-00 Rheumatoid Arthritis 1 2025-01-31
Phase I / II clinical trial, randomized, exploratory and prospective to evaluate the safety and efficacy of the transfusion of autologous TR… Recruiting

2024-519845-30-00 To evaluate the efficacy in the prevention of the rejec 1 2025-01-30
A study describing the efficacy and safety of belimumab administered subcutaneously in adult participants with early systemic lupus erythema… Recruiting

2023-509146-35-00 Systemic Lupus Erythematosus 6 2025-01-30
A multicenter, randomized, blinded, placebo controlled, phase II study to evaluate the safety and efficacy of cell therapy based with artifi… Recruiting

2023-505226-33-00 Presymptomatic diabetes type 1 (stage 1) 4 2025-01-28
IVIG-Spare Trial Recruiting

2024-513681-19-00 Polymyositis 4 2025-01-23
Prednisone treatment in acute interstitial nephritis (PRAISE) Recruiting

2024-520299-86-00 Acute interstitial nephritis 6 2025-01-22
A study to evaluate the efficacy and safety of frexalimab, brivekimig or rilzabrutinib in participants aged 16 to 75 years with primary foca… Recruiting

2024-511775-15-00 Immune system diseases 4 2025-01-17
Evaluate long-term safety, tolerability and efficacy of iptacopan in study participants with aHUS Recruiting

2022-502965-34-00 Atypical Hemolytic Uremic Syndrome (aHUS) 5 2025-01-08
EvER-ILD 3 : Evaluation of Efficacy and safety of Rituximab and mycophenolate mofetil combination in patients with Interstitial Lung Disease… Recruiting

2023-510507-21-00 Intersitial lung disease related to systemic sclerosis 10 2025-01-08
Phase I/II randomized clinical trial of allogeneic adipose tissue-derived mesenchymal stromal cells systemic infusion in severe systemic scl… Recruiting

2023-505977-34-00 Systemic sclerosis 4 2025-01-08
ANRS0392s ELDORADO : Phase III, open-label, randomized, multicenter trial EvaLuating the non-inferiority of DORAvirine versus DOlutegravir b… Recruiting

2023-508626-10-00 HIV-1 infection 5 2025-01-08
RIO Trial Recruiting

2024-514564-13-00 HIV 4 2025-01-02
Safety and efficacy of low-dose interleukin-2 therapy in chronic inflammatory barrier diseases (IL-2-ID) Recruiting

2023-510297-14-00 Primary Sclerosing Cholangitis (PSC) 4 2024-12-27
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared … Recruiting

2023-504022-19-01 Polymyositis or dermatomyositis according to 2017 EULAR 5 2024-12-13
Discontinuation of rituximab compared with rituximab maintenance in ANCA-associated vasculitis – a randomized non-blinded controlled trial (… Recruiting

2023-508398-10-00 ANCA-associated vasculitis 6 2024-12-12
A clinical trial to learn about the effects of YTB in people with difficult to treat active systemic lupus erythematosus (SLE), or active k… Recruiting

2023-510150-17-00 Active, refractory systemic lupus erythematosus (SLE), 4 2024-12-11
A Phase 2 study to Evaluate the Safety, Tolerability and Efficacy of Efgartigimod PH20 SC given by prefilled syringe in Kidney Transplant Re… Recruiting

2023-508180-72-00 Antibody-Mediated Rejection 4 2024-12-11
A Phase-2b, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-NMDA Receptor Enc… Recruiting

2023-504686-23-00 anti-N-methyl-D-aspartate receptor encephalitis (anti-N 4 2024-12-10